Metformin Monotherapy Not Always Best Start in Type 2 Diabetes
Metformin failure in people with type 2 diabetes is very common, particularly among those with high A1c levels at the ...
Metformin failure in people with type 2 diabetes is very common, particularly among those with high A1c levels at the ...
Readjudication of mortality data from the FOURIER trial suggests a higher risk for cardiovascular death with evolocumab (Repatha) among patients ...
A re-evaluation of cardiovascular risk management guidelines intended for use by rheumatologists may be warranted based on findings from a ...
A new coronary artery disease (CAD) "digital marker" can pinpoint gradients of risk on a spectrum, potentially improving CAD diagnosis ...
A multi-biomarker risk score helps predict increased risk for future cardiovascular (CV) events as well as high-risk anatomy at revascularization ...
Cardiorespiratory fitness emerged as a stronger predictor of all-cause mortality than did any traditional risk factor across the spectrum of ...
PCSK9 inhibitors, which are among the most effective therapies for reducing LDL cholesterol (LDL-C), are associated with a neutral effect ...
© 2022 Medical News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.
© 2022 Medical News Hubb All rights reserved.